Philadelphia, Pennsylvania--(Newsfile Corp. - February 26, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Kyndryl Holdings, Inc. (NYSE: KD). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Kyndryl shares prior to August 7, 2024, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. P ...

Core Viewpoint - The law firm Brodsky & Smith is investigating potential claims against the Board of Directors of SkyWater Technology, Inc. for possible breaches of fiduciary duty related to the company's sale to IonQ for $35.00 per share, which implies a total equity value of approximately $1.8 billion [1]. Group 1 - The investigation focuses on whether the SkyWater Technology Board failed to conduct a fair process and whether the deal consideration provides fair value to shareholders, as it is below the 52-week high of $36.27 for the company's shares [2]. - The transaction involves a cash-and-stock deal, raising concerns about the adequacy of the offer in relation to the company's market performance [1][2]. Group 2 - Brodsky & Smith is a litigation law firm with expertise in representing shareholders in securities and class action lawsuits, having successfully recovered millions for clients [3]. - The firm has been appointed as lead counsel in various class actions by numerous courts across the country, indicating its credibility and experience in handling such cases [3].

Core Viewpoint - Jamf Holding Corp. is under investigation for potential breaches of fiduciary duties by its board of directors in relation to a proposed take-private sale at a price of $13.05 per share, which may be considered unfairly low for shareholders [1][3]. Group 1: Investigation Details - The investigation is led by Bleichmar Fonti & Auld LLP, focusing on whether Jamf's board and Vista Equity Partners have acted in the best interests of shareholders regarding the acquisition by Francisco Partners Management, L.P. [5][3]. - Jamf's board did not form an independent special committee to assess the transaction, raising concerns about conflicts of interest, particularly since Vista owns 34.4% of Jamf's stock and has the right to appoint four out of nine board members [4][3]. Group 2: Shareholder Implications - Current shareholders of Jamf are encouraged to seek additional information and may have legal options available to them, as the firm operates on a contingency fee basis, meaning no upfront costs for shareholders [6][2]. - The acquisition deal is contingent upon a shareholder vote, but Vista has not been excluded from participating in that vote, which could further complicate the situation for minority shareholders [4][3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Capricor Therapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][2]. Group 1: Legal Investigation - The law firm is encouraging long-term stockholders of Capricor who suffered losses between October 9, 2024, and July 10, 2025, to discuss their legal rights [1]. - A class action complaint was filed against Capricor on July 17, 2025, focusing on the company's disclosures regarding its lead cell therapy candidate, deramiocel [2]. - The investigation centers on whether Capricor's board misled investors about the drug's regulatory status and safety data [2]. Group 2: Regulatory Issues - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - The CRL also highlighted outstanding issues in the Chemistry, Manufacturing, and Controls section of the application [3]. Group 3: Stock Performance - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marqeta, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2] Group 1: Lawsuit Details - The class action complaint was filed on December 9, 2024, covering a Class Period from May 7, 2024, to November 4, 2024 [1] - The lawsuit claims that Marqeta made false and misleading statements regarding regulatory challenges and subsequently had to cut its guidance for Q4 2024 [2] - Investors reportedly suffered damages when the true details about Marqeta's business outlook were revealed [2] Group 2: Contact Information - Long-term stockholders of Marqeta are encouraged to contact Bragar Eagel & Squire, P.C. for more information regarding the claims [3] - The law firm offers no cost or obligation for inquiries related to the investigation [3]

Core Viewpoint - Purcell & Lefkowitz LLP is investigating REX American Resources Corporation to determine if its directors breached fiduciary duties related to recent corporate actions [1] Group 1 - The investigation is on behalf of shareholders of REX American Resources Corporation [1] - The law firm specializes in representing shareholders affected by securities fraud and breaches of fiduciary duty [3] - Shareholders seeking more information can contact the firm directly for assistance [2]

Core Viewpoint - Purcell & Lefkowitz LLP is investigating The Ensign Group, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is on behalf of The Ensign Group's shareholders [1]. - The law firm specializes in representing shareholders affected by securities fraud and corporate misconduct [3]. - Shareholders can obtain additional information regarding their rights and options at no cost [2].